Drug Trial Radar · NCT05007392
A Study to Evaluate Efficacy of Dotinurad and Febuxostat for the Treatment of Participants With Gout
Last checked: Nov 19, 2026Latest source record: Jul 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
451
Actual
Start
Dec 21, 2021
Primary completion
Jun 14, 2023
Study completion Jun 14, 2023
Sponsor
- Lead sponsor
- Eisai Co., Ltd.Eisai
- Sponsor type
- Industry
- First posted
- Aug 16, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of the study is to confirm the efficacy of dotinurad 4 milligram (mg) to febuxostat 40 mg on the percentage of participants achieving a serum uric acid (SUA) level less than or equal to (\<=) 6.0 milligrams per deciliter (mg/dL) at Week 24 in Chinese participants with gout.
Conditions
- Gout
Interventions
DotinuradDrug
Dotinurad oral tablets.
FebuxostatDrug
Febuxostat oral tablets.
Dotinurad Matched PlaceboOther
Dotinurad matched placebo oral tablets.
Febuxostat Matched PlaceboOther
Febuxostat matched placebo oral tablets.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Serum Uric Acid (SUA) Level <=6.0 mg/dL at Week 24 (LOCF)Time frame: At Week 24
Locations
30 sites in 1 country. Site status is shown where the registry gives one.
Anhui Provincial Hospital
Hefei, Anhui, China
Beijing Anzhen Hospital,Capital Medical University
Beijing, Beijing Municipality, China
Beijing Hospital
Beijing, Beijing Municipality, China
Peking University First Hospital
Beijing, Beijing Municipality, China
Beijing Tongzhou District Luhe Hospital, Beijing, P.R.China
Beijing, Beijing Municipality, China
Foshan First People's Hospital
Foshan, Guangdong, China
Guangzhou First People's Hospital
Guangzhou, Guangdong, China
Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong, China
Jieyang People's Hospital
Jieyang, Guangdong, China
The Seventh Affiliated Hospital of Sun Yat-sen University
Shenzhen, Guangdong, China
Shenzhen People's Hospital
Shenzhen, Guangdong, China
Hainan General Hospital
Haikou, Hainan, China
The Third Xiangya Hospital of Central South University
Changsha, Hu'nan, China
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology
Wuhan, Hubei, China
First Affiliated Hospital of Inner Mongolia technological University
Baotou, Inner Mongolia, China
The Affiliated Hospital of Inner Mongolia Medical University
Hohhot, Inner Mongolia, China
The First People's Hospital of Changzhou
Changzhou, Jiangsu, China
Nanjing Medical University Affiliated 2nd Hospital
Nanjing, Jiangsu, China
Northern Jiangsu People's Hospital
Yangzhou, Jiangsu, China
Jiangxi Pingxiang People's Hospital
Pingxiang, Jiangxi, China
Jilin Province People's Hospital
Changchun, Jilin, China
The First Hospital of Jilin University
Changchun, Jilin, China
Yanbian University Hospital
Yanji, Jilin, China
The First Affiliated Hospital of Dalian Medical University
Dalian, Liaoning, China
Dalian Municipal Central Hospital Affiliated of Dalian Medical University
Dalian, Liaoning, China
The Second Hospital of Dalian Medical University
Dalian, Liaoning, China
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, China
Tong Ren Hospital Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China
Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine
Shanghai, Shanghai Municipality, China
The First People's Hospital of Yunnan Province
Kunming, Yun'nan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.